<div id="readability-page-1"><p>Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report)'s share price shot up 0.7% during trading on Wednesday . The stock traded as high as $1.4099 and last traded at $1.40. 76,328 shares were traded  during mid-day trading, a decline of 61% from the average session volume of 195,954 shares. The stock had previously closed at $1.39.</p><div><p><span></span><span>Get <strong>Tiziana Life Sciences</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><p>Separately, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Tiziana Life Sciences in a report on Wednesday, January 21st. One research analyst  has rated the stock with a Sell rating,  According to MarketBeat.com, the company presently has an average rating of &#34;Sell&#34;.</p><p><b>Get Our Latest Stock Analysis on TLSA</b></p><h2>Tiziana Life Sciences Stock Performance</h2><p>The firm's 50-day moving average is $1.51 and its two-hundred day moving average is $1.76. </p><h2>Institutional Investors Weigh In On Tiziana Life Sciences</h2><p>A number of institutional investors and hedge funds have recently made changes to their positions in TLSA. Rachor Investment Advisory Services LLC acquired a new stake in shares of  Tiziana Life Sciences during the fourth quarter worth about $25,000.  Cubist Systematic Strategies LLC acquired a new stake in  Tiziana Life Sciences during the 1st quarter worth approximately $25,000.  Marshall Wace LLP acquired a new stake in  Tiziana Life Sciences during the 2nd quarter worth approximately $39,000.  HRT Financial LP purchased a new position in  Tiziana Life Sciences in the 4th quarter valued at approximately $36,000.  Finally, ARS Investment Partners LLC acquired a new position in shares of  Tiziana Life Sciences in the third quarter worth $66,000. </p><h2>About Tiziana Life Sciences</h2> (Get Free Report)<p>Tiziana Life Sciences plc <span>NASDAQ: TLSA<span></span></span> is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.  </p><p>The company's lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.</p><h2>See Also</h2><ul><li>Five stocks we like better than Tiziana Life Sciences</li><li>Have $500? Invest in Elon’s AI Masterplan</li><li>Your Bank Account Is No Longer Safe</li><li>Silver paying 20% dividend. Plus 68% share gains</li><li>The Fed Just Got Kneecapped — Here’s What Happens Next</li><li>This $15 Stock Could Go Down as the #1 Stock of 2026</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Tiziana Life Sciences Right Now?</h2><p>Before you consider Tiziana Life Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.</p><p>While Tiziana Life Sciences currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Tiziana Life Sciences (NASDAQ:TLSA) shares rose 0.7% to $1.40 during trading, with a volume decline of 61% from the average. Analysts have a "Sell" rating on the stock, with Weiss Ratings reaffirming a "sell (d-)" rating. Institutional investors have recently acquired stakes in the company, which focuses on developing therapeutics for oncology and infectious diseases. Despite the stock's slight increase, it is not favored by top analysts, who recommend other stocks instead.</p>

Market Beat

VG Health

Health Care Select Sector SPDR

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Tiziana Life Sciences

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

iShares Global Healthcare

Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 0.7%  - Here's What Happened